Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2010

View Archived Issues

Clinical data indicate RTS,S/AS01E malaria vaccine is safe in infants and children

Phase I/IIa trial evaluates prime-boost vaccination with AdCh63-MSP1 and MVA-MSP1 malaria vaccines

Phase I/II trial shows safety of PfSPZ malaria vaccine in healthy volunteers

Neuraltus Pharma receives grants under QTDP

Pevion Biotech reports preliminary data from phase I PEV-7 trial

Flt3L level in CSF is putative biomarker for primary fibromyalgia and Sjogren's syndrome

Genome-wide meta-analysis suggests involvement of PGC-1-alpha in Parkinson's disease

Wyeth discovers new inhibitors of PI3K-alpha and mTOR

S-47445 to advance to phase I trials for neurogenerative diseases

Eisai claims novel cytidine deaminase inhibitors

Resolve Therapeutics licenses agents for autoimmune disease from University of Washington

Forest Labs and Janssen collaborate on Bystolic and Savella

GlobeImmune receives Federal Therapeutic Discovery Project Program grants

Emergent BioSolutions receives grants for oncology and autoimmunity programs

Pfizer claims new agonists of prostanoid EP2 and EP4 receptors

Infinity Pharma patents new inhibitors of fatty-acid amide hydrolase 1

Oligomerix obtains phase II NIH grant for Alzheimer's disease drug discovery

Ceregene raises funds to further develop CERE-120 and CERE-110

Merck Serono's Saizen recommended for approval in Europe

Cerulean Pharma closes series C financing led by Lilly Ventures

Epeius Biotech gets U.S. federal grant to further develop Rexin-G

Aires Pharma completes series B financing and enters option agreement with Novartis

Santarus launches Cycloset in U.S. to improve glycemic control in type 2 diabetes

Bausch & Lomb begins phase IIb trial of BOL-303259-X for reduction of intraocular pressure

Enrollment complete in phase IIb trial of V-5 immunitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...